pactimibe

Subscribe to Selected New Research on pactimibe

4 relevant articles (0 outcomes, 0 trials/studies) found for this Bio-Agent

Also Known As:

(7-(2,2-dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl)acetic acid hemisulfate; CS-505; pactimibe sulfate

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

2-Ring Heterocyclic Compounds

Indoles: 69

Indoleacetic Acids: 129

pactimibe: 4

Heterocyclic Acids

Indoleacetic Acids: 129

pactimibe: 4

Related Diseases

1.	Atherosclerosis (Atheroma) 03/23/2006 - "The atheroma volume in the most diseased 10-mm subsegment regressed by 3.2 mm3 in the placebo group, as compared with a decrease of 1.3 mm3 in the pactimibe group (P=0.01)" 03/23/2006 - "As compared with baseline values, the normalized total atheroma volume showed significant regression in the placebo group (-5.6 mm3, P=0.001) but not in the pactimibe group (-1.3 mm3, P=0.39; P=0.03 for the comparison between groups)" 03/23/2006 - "RESULTS: The primary efficacy variable analyzing the progression of atherosclerosis--the change in percent atheroma volume--was similar in the pactimibe and placebo groups (0.69 percent and 0.59 percent, respectively; P=0.77)" Get all the results and reference details, order at left...
2.	Hypercholesterolemia 08/01/2008 - "Pactimibe sulfate is a novel acyl coenzyme A:cholesterol acyltransferase inhibitor developed for the treatment of hypercholesterolemia and atherosclerotic diseases" Get all the results and reference details, order at left...
3.	Coronary Disease (Coronary Heart Disease) 06/06/2006 - "Although pactimibe did not alter serum cholesterol levels in WHHL rabbits, it stabilized vulnerable plaque characterized with reduced cholesteryl ester content, enriched collagen fibers and increased smooth muscle cells, indicating potential as a treatment strategy for coronary heart disease." Get all the results and reference details, order at left...
4.	Coronary Artery Disease (Coronary Atherosclerosis) 07/01/2006 - "METHODS: Five hundred thirty-four subjects with established coronary artery disease on angiography were randomized to receive the experimental ACAT inhibitor, pactimibe, 100 mg daily or matching placebo for 18 months" Get all the results and reference details, order at left...
4 Diseases and 4 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Collagen
2.	Sterol O-Acyltransferase
3.	Cholesterol
4.	Acyl Coenzyme A (Acyl CoA)
4 Drugs and Important Bio-Agents and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>